The last time the FDA approved a new prescription treatment for pattern baldness, Bill Clinton was president and the term "biotech IPO" still carried some mystique. Nearly three decades later, a New Haven startup believes it has the formula to break that dry spell—and investors, at least for now, seem willing to bet heavily on the possibility.
Veradermics, a clinical-stage biotech developing an extended-release oral pill for hair regrowth, raised roughly $295 million in an initial public offering that defied the cautious mood hanging over early 2026's public markets. Shares priced at $17 on February 4—above the company's $14 to $16 target range—then promptly more than doubled, closing their first trading session at $37.75. That 122% pop signals either genuine enthusiasm or the kind of froth that makes underwriters quietly pleased they didn't leave more money on the table.
Trading under the ticker MANE on the New York Stock Exchange (a branding choice that borders on too cute), the company sold 15,077,647 shares in the base offering, generating $256.3 million before underwriters exercised their full overallotment option. Another 2,261,647 shares brought total gross proceeds to $294.8 million. Not bad for a company founded by dermatologists just seven years ago and still years away from generating its first dollar of revenue.
Wellington Management had indicated interest in buying up to $30 million worth of shares, while pharmaceutical giant Eli Lilly signaled appetite for as much as 4.9% of the post-offering equity, according to prospectus filings. Such indications are non-binding, of course. Still, Lilly's interest carries weight—the kind of validation that reminds institutional investors this isn't just another speculative play on vanity.
A Market Frozen in Time
What Veradermics is chasing isn't small. An estimated 80 million Americans experience pattern hair loss, a market that some analysts project will eclipse $30 billion by 2028. Yet the prescription landscape has remained remarkably static. The only FDA-approved options—topical minoxidil and finasteride, the latter a hormonal therapy limited to men—date back decades. For women, no oral prescription treatment exists at all.
That stagnation has left room for off-label prescribing, over-the-counter solutions of varying efficacy, and a sprawling wellness industry peddling everything from laser caps to dubious supplements. It's a gap Veradermics hopes to fill with VDPHL01, its lead candidate.
The drug is essentially minoxidil—yes, the same active ingredient found in Rogaine—but reformulated as an extended-release oral pill. The distinction matters. Immediate-release oral minoxidil, sometimes prescribed off-label by dermatologists, can cause blood pressure swings and unwanted side effects tied to concentration spikes. Veradermics claims its formulation sidesteps those peaks while keeping drug levels consistently above what it describes as a "hair-growth threshold." Whether that translates to meaningfully better outcomes than topical alternatives or carefully dosed immediate-release versions remains the multi-billion-dollar question.
Three Shots on Goal
The company isn't placing all its chips on a single trial. Veradermics is currently running three Phase 3 studies across male and female patient populations—an ambitious strategy that accelerates timelines but also multiplies risk and cost.
Its male Phase 2/3 registration-directed trial, tracked under identifier NCT06724614, enrolled roughly 480 participants across 44 U.S. sites. Enrollment wrapped in December 2025, with primary data expected as soon as this month. A second Phase 3 trial in men is actively recruiting. Then there's the November 2025 launch of what Veradermics touts as the first U.S. Phase 3 trial of an oral hair loss treatment specifically for women—a study targeting more than 500 enrollees.
Early glimpses have been encouraging, if limited in scope. Preliminary data from 21 male participants taking 8.5 milligrams twice daily showed an average gain of 47.3 non-vellus hairs per square centimeter after four months. (Non-vellus hairs are the thick, pigmented kind you actually want on your scalp.) Roughly 90.5% reported subjective improvement. No serious adverse events or cardiac concerns surfaced in that subset as of October 2025, though the sample size is, obviously, modest.
Full Phase 2 results covering both male and female cohorts are slated for sometime in 2026. The IPO proceeds will bankroll those ongoing trials and lay groundwork for a New Drug Application submission—assuming the data cooperates.
Moving Fast, Burning Capital
Veradermics has sprinted through financing rounds with a pace that suggests either shrewd timing or mounting urgency. The company, founded by dermatologists in 2019, pulled together a $75 million Series B led by Suvretta Capital Management in December 2024. Less than a year later, it closed an oversubscribed $150 million Series C led by SR One, drawing heavyweights like Viking Global Investors, Marshall Wace, and Invus, alongside existing investors Longitude Capital and Surveyor Capital, a Citadel affiliate.
That breakneck fundraising cadence reflects the realities of late-stage biotech development: trials are expensive, and the clock ticks loudly once you've started dosing patients. For the nine months ended September 30, 2025, Veradermics reported zero revenue and a net loss of $48.1 million, according to Barron's. Hardly unusual for a clinical-stage company, but a reminder that cash burn is very real.
Jefferies, Leerink Partners, Citigroup, and Cantor served as underwriters. At the IPO pricing, Renaissance Capital pegged the company's fully diluted market cap at approximately $606 million, with an enterprise value around $259 million after accounting for the fresh capital raised.
Competition Stirs After Decades of Silence
Veradermics isn't alone in sensing opportunity. After years of stagnation, the hair loss treatment pipeline is showing signs of life.
Cosmo Pharmaceuticals announced positive Phase 3 topline results in December 2025 for clascoterone, a topical androgen receptor inhibitor targeting male pattern baldness, and plans regulatory submissions in the near term. Kintor Pharmaceutical is advancing GT20029, an androgen receptor degrader, through Phase 2 trials. Pelage Pharmaceuticals has PP405, which employs a stem-cell activation mechanism, also in earlier-stage testing.
Whether any of these approaches—or Veradermics' reformulated minoxidil—will prove meaningfully superior to existing options is the question keeping investors and patients equally curious. The FDA hasn't exactly been in a rush to expand its hair loss arsenal. Perhaps that changes if the data is compelling enough.
For now, Veradermics has capital, momentum, and a ticker symbol that's either clever or cringe-inducing depending on your tolerance for biotech branding. The hard part—proving the science works at scale—comes next.
